BRAINSTORM CELL THERAPEUTICS INC.
BCLI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCLI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCLI
Brainstorm Cell Therapeutics Inc. is a clinical-stage biotechnology company developing its proprietary NurOwn® treatment candidate for ALS and other neurodegenerative diseases, currently trading on the OTCQB Venture Market after Nasdaq delisting and facing significant capital constraints.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for BRAINSTORM CELL THERAPEUTICS INC..
Brainstorm Cell Therapeutics Inc. is a clinical-stage biotechnology company developing its proprietary NurOwn® treatment candidate for ALS and other neurodegenerative diseases, currently trading on the OTCQB Venture Market after Nasdaq delisting and facing significant capital constraints.
- Cash and equivalents of $0.2M as of 2026-06-30 [sec].
- Net loss of -$3.9M for the period ended 2026-06-30 [sec].
- Shareholders' equity of -$7.8M as of 2026-06-30 [sec].
- Total debt of $1.3M as of 2026-06-30 [sec].
- Company has not generated revenues from its activities and has incurred substantial operating losses [sec · filed 2026-05-21].
What works
- The company has an SPA (Special Protocol Assessment) with the FDA for a Phase 3b trial in ALS, indicating regulatory alignment on trial design [sec_mda · as of 2026-08-14].
- Management has been successful in raising financing in the past, including through recent SPAs [sec_mda · as of 2026-05-15].
- The company is considering multiple capital-raising alternatives, including equity sales, warrants, and convertible notes [sec · filed 2023-11-14].
What to weigh
- Existing cash is insufficient to fund operations for at least twelve months, and the company expects to need substantial additional financing [sec · filed 2023-11-14].
- The company's common stock has been delisted from Nasdaq and now trades on the OTCQB Venture Market, which may limit liquidity and stock price [sec · filed 2026-05-21].
- There is no assurance that additional funding will be available on favorable terms or at all [sec · filed 2026-05-21].
- The company has not generated any revenues and continues to incur operating losses, with negative cash flow from operations [sec · filed 2026-05-21].
From the filings
Quoted directly from source documents.
Company needs additional capital to fund Phase 3b trial and commercialization
“additional capital raises will be needed to conduct a Phase 3b trial in ALS, to commercialize NurOwn® for ALS”
SEC MD&A · August 14, 2026
Stock delisted from Nasdaq, now on OTCQB
“The Company's common stock has been delisted from the Nasdaq and now trades on the OTCQB Venture Market”
SEC MD&A · March 31, 2026
No revenues and substantial operating losses
“the Company has not generated revenues from its activities and has incurred substantial operating losses”
SEC filings · May 21, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Existing cash is insufficient to fund operations for at least twelve months; substantial additional capital needed [sec · filed 2023-11-14].
- Nasdaq delisting and OTCQB trading — Delisting from Nasdaq and move to OTCQB may limit liquidity and stock price [sec · filed 2026-05-21].
- Financing uncertainty — No assurance that additional funding will be available on favorable terms or at all [sec · filed 2026-05-21].
- No revenue generation — Company has not generated any revenues and continues to incur operating losses [sec · filed 2026-05-21].
What to watch
- Ability to raise additional capital to fund Phase 3b trial and commercialization [sec_mda · as of 2026-08-14].
- Progress of regulatory interactions with FDA regarding NurOwn® for ALS [sec_mda · as of 2026-03-31].
- Outcome of putative securities class action and derivative lawsuits [sec · filed 2026-05-21].
- Potential impact of Nasdaq delisting on stock liquidity and financing options [sec · filed 2026-05-21].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run BRAINSTORM CELL THERAPEUTICS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BRAINSTORM CELL THERAPEUTICS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
0.8 months
OCF -$895K · Net income -$4M
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 6.5%
- Days to cover
- 1.3
- Shares short
- 604,460
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCLI short interestGovernance
Frequently asked questions
What is the AI investment thesis for BRAINSTORM CELL THERAPEUTICS INC.?
Brainstorm Cell Therapeutics Inc. is a clinical-stage biotechnology company developing its proprietary NurOwn® treatment candidate for ALS and other neurodegenerative diseases, currently trading on the OTCQB Venture Market after Nasdaq delisting and facing significant capital constraints.
What is BRAINSTORM CELL THERAPEUTICS INC.'s lead drug candidate?
BRAINSTORM CELL THERAPEUTICS INC.'s most advanced tracked candidate is nurown (Preclinical) for Alzheimer's disease (AD).
Who is the CEO of BRAINSTORM CELL THERAPEUTICS INC.?
Mr. Chaim Lebovits is the chief executive officer of BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
Where is BRAINSTORM CELL THERAPEUTICS INC. headquartered?
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) is headquartered in New York, NY, United States.
What therapeutic areas does BRAINSTORM CELL THERAPEUTICS INC. focus on?
BRAINSTORM CELL THERAPEUTICS INC. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.